MORRISVILLE, N.C., March 15, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced financial results for the three and nine month periods ending January 31, 2012. In addition to disclosing results in accordance with United States (U.S.) Generally Accepted Accounting Practices (GAAP), this report contains certain non-GAAP financial measures that management believes are helpful in understanding and comparing the company’s past financial performance and future results.
